Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice
- 693 Downloads
Eltrombopag is safe and effective in primary chronic ITP. However, lack of clinical trials avoids a clear demonstration of its utility in newly diagnosed and persistent ITP. Our aim here is to report Spanish results for this type of patients. We retrospectively evaluated 220 adult primary ITP patients. According to standard definition, patients were allocated to newly diagnosed (n = 30), persistent (n = 30), and chronic (n = 160) ITP. Groups were homogenous regarding most relevant parameters. 180 (90%) of 220 patients achieved a platelet response (R) with 167 (75.9%) complete responses (CR) after a 15-month follow-up. No statistical significant differences among groups but a trend towards a greater efficacy in newly diagnosed ITP were observed (93.3% of responses with 86.7% of CR). Efficacy in persistent ITP (83.3% of responses with 80.0% of CR) and chronic ITP (79.4% of responses with 73.1% of CR) was similar. 70 patients (31.8%) experienced adverse events. 15 of them were grade 3–4. Most common adverse effects were headache and hepatobiliary laboratory abnormalities (HBLAs). One persistent ITP had a venous thrombosis and one chronic ITP had grade II myelofibrosis. We consider Eltrombopag use for the early stage ITP as effective and safe as it is in chronic ITP.
KeywordsImmune Thrombocytopenia ITP Thrombopoietin TPO
We are grateful to Alicia García-García and Raquel Ranedo-Zaldo for their attention to some technical aspects.
Conception and design: TJGL and JRGP; data collection: all authors; statistical analysis: TJGL and JRGP; analysis and interpretation of results: all authors; writing article (text and tables): JRGP and TJGL; final approval of article: all authors.
Compliance with ethical standards
Conflict of interest
The authors declare no competing financial interests.
- 18.Mitsuhashi K, Ishiyama M, Imai Y, Shiseki M, Mori N, Teramura M, et al. Combined romiplostim and intravenous immunoglobulin therapy increased platelet count, facilitating splenectomy in a patient with refractory immune thrombocytopenic purpura unresponsive to monotherapy. Br J Haematol. 2012;158:798–800.CrossRefPubMedGoogle Scholar
- 22.Godeau B, Chevret S, Varet B, Lefrère F, Zini JM, Bassompierre F, et al. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet. 2002;359:23–9.CrossRefPubMedGoogle Scholar
- 23.Despotovic JM, Neunert CE. Is anti-D immunoglobulin still a frontline treatment option for immune thrombocytopenia? Hematol Am Soc Hematol Educ Program. 2013;2013(1):283–5.Google Scholar
- 29.Gómez-Almaguer D, Tarín-Arzaga L, Moreno-Jaime B, Jaime-Pérez JC, Ceballos-López AA, Ruiz-Argüelles GJ, et al. High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. Eur J Haematol. 2013;90:494–500.CrossRefPubMedGoogle Scholar
- 30.Bussel JB, Lee CS, Seery C, Imahiyerobo AA, Thompson MV, Catellier D, et al. Rituximab and three dexamethasone cycles provide responses similar to splenectomy in women and those with immune thrombocytopenia of less than two years duration. Haematologica. 2014;99:1264–71.CrossRefPubMedPubMedCentralGoogle Scholar